CONCOMITANT ALPHA-INTERFERON AND CHEMOTHERAPY IN ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK

被引:10
作者
BENASSO, M
MERLANO, M
BLENGIO, F
CAVALLARI, M
ROSSO, R
TOMA, S
机构
[1] Div. Oncologia Medica I, Isto. Naz. per la Ricerca sul Cancro, 16132 Genoa, Viale Benedetto XV
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1993年 / 16卷 / 06期
关键词
ALPHA-INTERFERON; HEAD AND NECK;
D O I
10.1097/00000421-199312000-00001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The combination of chemotherapy and interferons has been tested in several human tumors but, until now, no clinical data have been reported in head and neck cancer. At the Istituto Nazionale per la Ricerca sul Cancro of Genoa, 14 patients with previously treated SCC-HN underwent the following regimen: cisplatin, 20 mg/m2/day, 5-fluorouracil, 200 mg/m2/day i.v. bolus and recombinant interferon-alpha-2b (r-IFN-alpha-2b) (Intron-A, Shering-Plough), 3 MIU/day i.m., for 5 consecutive days. Recombinant IFN-alpha-2b was also administered, at the same dosage, 3 times per week during the 2 weeks interval among cycles. Grade III-IV hematological toxicity was recorded in 43% of patients. Increasing fatigue, anorexia, and flu-like symptoms were experienced by most patients. For these reasons 9 of 14 patients needed a chemotherapy delay and a r-IFN-alpha-2b discontinuation. Therefore, due to the heavy toxicity observed, accrual was terminated early. The overall response rate was 54% (31% CR, 23% PR). Among the 5 patients who never delayed chemotherapy and discontinued r-IFN-alpha-2b, all but one responded. In conclusion, a synergistic activity between chemotherapy and r-IFN-alpha-2b in head and neck cancer cannot be excluded, but, in our opinion, further investigations should consider less aggressive regimens and/or more selected patients.
引用
收藏
页码:465 / 468
页数:4
相关论文
共 13 条
  • [1] ARYA SK, 1984, J IMMUNOL, V133, P273
  • [2] CARMICHAEL J, 1986, CANCER RES, V46, P4916
  • [3] KISH JA, 1984, CANCER, V53, P1819, DOI 10.1002/1097-0142(19840501)53:9<1819::AID-CNCR2820530903>3.0.CO
  • [4] 2-R
  • [5] MAINTENANCE TREATMENT WITH RECOMBINANT INTERFERON ALFA-2B IN PATIENTS WITH MULTIPLE-MYELOMA RESPONDING TO CONVENTIONAL INDUCTION CHEMOTHERAPY
    MANDELLI, F
    AVVISATI, G
    AMADORI, S
    BOCCADORO, M
    GERNONE, A
    LAUTA, VM
    MARMONT, F
    PETRUCCI, MT
    TRIBALTO, M
    VEGNA, ML
    DAMMACCO, F
    PILERI, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (20) : 1430 - 1434
  • [6] CLINICAL-RESULTS OF LEUKOCYTE INTERFERON-INDUCED TUMOR-REGRESSION IN RESISTANT HUMAN METASTATIC CANCER RESISTANT TO CHEMOTHERAPY AND OR RADIOTHERAPY-PULSE THERAPY SCHEDULE
    MEDENICA, R
    SLACK, N
    [J]. CANCER DRUG DELIVERY, 1985, 2 (01): : 53 - 76
  • [7] MERLANO M, 1987, CANCER TREAT REP, V71, P485
  • [8] MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO
  • [9] 2-6
  • [10] SHIRINIAN M, 1992, P ASCO, V11, P807